CAI Caris Corp: רווח למניה בשנים עשר החודשים האחרונים

Caris Life Sciences, Inc. (CAI) automates the search for cancer markers via AI platforms, which, combined with the recognition of molecular profiling by insurers, ensures a steady inflow of capital. The current YoY TTM EPS growth trend demonstrates profit dynamics, where the current value stands at 114.10. Business stability is supported by robust intellectual property protection and an absence of geopolitical risks within the US.
CAI (carislifesciences.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Year-over-year (TTM) EPS growth measures the rate of change in net income per share over a rolling twelve-month period. By analyzing the history of EPS YoY (TTM) percentage changes, an investor can observe the actual dynamics of business scaling. The current value of 114.10 reflects the sensitivity of earnings to operating expenses and market demand. For Caris Life Sciences, Inc. (CAI), this metric confirms the effectiveness of its premium pricing strategy for unique molecular diagnostics.